CareDx (CDNA) Q2 FY26 earnings call

CareDx delivered a strong second quarter, driven by robust growth in its core transplant testing services and strategic advancements in its pipeline and recent NavDx acquisition. The company raised its full-year revenue and adjusted EBITDA guidance, reflecting confidence in its precision molecular diagnostics model and the successful integration of new businesses. Management is focused on expanding market access and leveraging its commercial and operational scale to drive future profitability.